IAAONCDD: Improvement and Application of New Closed Drainage Device

Sponsor
Yongxin Zhou (Other)
Overall Status
Unknown status
CT.gov ID
NCT04143360
Collaborator
(none)
100
2
18

Study Details

Study Description

Brief Summary

According to the problems of traditional closed thoracic drainage in clinical work, this study aims to further improve and improve the new closed thoracic drainage system by changing the material of drainage tube, increasing the regulating valve of external fixator and increasing the gas flow monitoring kit for special patients, so as to expand its clinical application scope and formulate its operation. Standardize. At the same time, through a randomized controlled study, the simplicity, effectiveness and safety of the new minimally invasive thoracic closed drainage system developed by the research group were deeply studied.

Condition or Disease Intervention/Treatment Phase
  • Device: New Closed Drainage Device
  • Device: Traditional closed drainage device
N/A

Detailed Description

The traditional closed thoracic drainage method has complex operation and high technical requirements. It has obvious pain during and after operation. Operational complications such as tissue organs, intercostal vessels and nerve injury may occur during the operation. Accidents may also occur after catheterization, including leakage around thoracic drainage tube, thoracic drainage tube prolapse, subcutaneous emphysema and accumulation. Liquid; To solve these problems, we have invented "minimally invasive thoracic closed drainage system" through a number of patent designs, including: thoracic closed drainage tube implantation expansion forceps, double-chamber thoracic drainage device with side balloon, guide wire, puncture needle, various types of dilators, chest tube fixation devices, etc. The system has the characteristics of minimally invasive puncture and implantation of drainage tube, safe, fast operation, no need of suture and fixation, good position of drainage tube after implantation, less pain for patients, and closing incision in the medial part of patients, avoiding leakage and subcutaneous emphysema and hydrops.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Improvement and Clinical Application of a New Minimally Invasive Closed Thoracic Drainage System
Anticipated Study Start Date :
Apr 1, 2020
Anticipated Primary Completion Date :
Sep 30, 2021
Anticipated Study Completion Date :
Sep 30, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: New Closed Drainage Device

We further improve the new closed thoracic drainage system by changing the material of drainage tube, adding external fixator control valve and increasing the gas flow monitoring kit for special patients, and apply it in clinical practice.

Device: New Closed Drainage Device
For the first group, a new closed drainage device was adopted.

Experimental: Traditional Closed Drainage Device

We use traditional closed drainage devices for patients with hemothorax and pneumothorax.

Device: Traditional closed drainage device
For group 2, conventional closed drainage device was used.

Outcome Measures

Primary Outcome Measures

  1. Total drainage time [up to 24 weeks]

    Efficiency of treatment

  2. Pulmonary reexpansion ratio [up to 24 weeks]

    Pulmonary reexpansion ratio

Secondary Outcome Measures

  1. VAS pain score during and after operation [up to 24 weeks]

    0 points means no pain; 1 points - 3 points means mild pain that patients can tolerate; 4 points - 6 points means pain affect sleep, but patients can tolerate;7 points - 10 points: means patients have gradually strong pain, which have affected appetite and sleep.

Other Outcome Measures

  1. Operation time of thoracentesis [up to 24 hours]

    Operation time of thoracentesis

  2. Percentage of lung recruitment on day 1 and 3 [up to 24 weeks]

    Percentage of lung recruitment

  3. Operational-related complications [up to 24 weeks]

    Incidence of loss of thoracic wall nerves, intercostal vessels and thoracic and abdominal organs

  4. Incidence of related accidents after catheterization [up to 24 weeks]

    Incidence rate of peri-drainage tube exudation, drainage tube falling off, drainage tube obstruction and subcutaneous emphysema

  5. The size of the wound [up to 24 weeks]

    The size of the wound

  6. infection of the wound [up to 24 weeks]

    infection of the wound

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
The selection criteria were as follows:
  • age 18-70 years, gender is not limited;

  • subjects clearly understand the purpose of the study, are willing and able to comply with the requirements to complete the study and sign the informed consent;

  • 18 Kg/m2 < BMI < 25 Kg/m2;

  • patients who need thoracic closed drainage for exhaust and drainage because of pneumothorax volume > 30%;

  • subjects did not have serious chest wall deformities.

Exclusion criteria:
  • Patients at high risk of bleeding, including patients with congenital hemophilia, thrombocytopenia (PLT < 50 *109/L), platelet dysfunction (such as idiopathic thrombocytopenic purpura, disseminated intravascular coagulation, congenital platelet dysfunction);

  • Cardiopulmonary function is poor, which is not suitable for the participants.

  • Patients with other infectious diseases (inflammation, tuberculosis) or empyema in the thoracic cavity;

  • Infection of skin around puncture and drainage;

  • Participated in other clinical trials within 30 days;

  • Other reasons why the researchers think it is inappropriate to participate in the experiment.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Yongxin Zhou

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Yongxin Zhou, Director, Shanghai Tongji Hospital, Tongji University School of Medicine
ClinicalTrials.gov Identifier:
NCT04143360
Other Study ID Numbers:
  • 2018-LCYJ-012
First Posted:
Oct 29, 2019
Last Update Posted:
Feb 18, 2020
Last Verified:
Feb 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 18, 2020